vorinostat has been researched along with Anemia, Refractory, with Excess of Blasts in 1 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
Anemia, Refractory, with Excess of Blasts: Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 9.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
| "This phase I study was conducted to identify the maximum-tolerated dose (MTD) of alvocidib when combined with vorinostat in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2." | 5.17 | A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. ( Ames, MM; Doyle, A; Grant, S; Holkova, B; Honeycutt, C; Kmieciak, M; McGovern, RM; Perkins, EB; Ramakrishnan, V; Reid, JM; Roberts, JD; Sankala, H; Shapiro, GI; Shrader, E; Supko, JG; Tombes, MB; Wellons, MD; Wright, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Holkova, B | 1 |
| Supko, JG | 1 |
| Ames, MM | 1 |
| Reid, JM | 1 |
| Shapiro, GI | 1 |
| Perkins, EB | 1 |
| Ramakrishnan, V | 1 |
| Tombes, MB | 1 |
| Honeycutt, C | 1 |
| McGovern, RM | 1 |
| Kmieciak, M | 1 |
| Shrader, E | 1 |
| Wellons, MD | 1 |
| Sankala, H | 1 |
| Doyle, A | 1 |
| Wright, J | 1 |
| Roberts, JD | 1 |
| Grant, S | 1 |
1 trial available for vorinostat and Anemia, Refractory, with Excess of Blasts
| Article | Year |
|---|---|
A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2.
Topics: Acute Disease; Adult; Aged; Anemia, Refractory, with Excess of Blasts; Antineoplastic Combined Chemo | 2013 |